Imugene (IMU) EGM 2025 summary

Opening remarks and agenda

• Meeting opened with acknowledgment of traditional landowners, confirmation of quorum, and proper constitution, held on 26 June 2025 as a hybrid event with instructions for virtual participation and voting.

• Board and management team introduced, including CEO, CFO, non-executive directors, and keynote speaker Dr. Jakob Dupont.

• Agenda included two formal resolutions, a short presentation, and a Q&A session.

Specific resolutions to be voted on

• Resolution 1: Approval of share consolidation as an ordinary resolution.

• Resolution 2: Approval to issue new shares to placement shareholders.

• Voting conducted by poll, with proxies representing 14.5% of issued capital; Resolution 1 carried with 85.94% in favor, Resolution 2 with 77% in favor (corrected from 97%).

Board and executive committee updates

• CEO provided updates on three drug candidates: AZERCELL (CAR T therapy), OnCar Lytics, and CF33.

• AZERCELL showed a 57% complete response rate in Phase 1B, with plans for Phase 2/3 trial in 2026.

• OnCar Lytics and CF33 both in Phase 1, with encouraging early data; pivotal Phase 2/3 trial for CF33 anticipated in 2026, pending data and regulatory approvals.

• Dr. Jakob Dupont scheduled as keynote speaker at major biotech and healthcare conferences.